Skip to main content

Advertisement

SpringerLink
Log in

Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

For decades, intravesical dimethyl sulfoxide (DMSO) cocktail therapy has been used for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS), but little is known about its long-term efficacy. We aimed to assess the long-term efficacy of intravesical DMSO/heparin/hydrocortisone/bupivacaine therapy in patients with IC/BPS.

Methods

Patients with IC/BPS from our institutions who underwent this therapy with >2 years follow-up were surveyed with O’Leary–Sant interstitial cystitis symptom and problem index questionnaires before and after therapy. Chart reviews and telephone surveys were then conducted to determine their posttherapy course.

Results

Of 68 eligible women, 55 (80.0%) with a median follow-up of 60 months (range 24–142) were surveyed. Their mean age at therapy onset was 44.8 years and their mean body mass index was 26.2 kg/m2. There were statistically significant improvements in O’Leary–Sant and pain scores of 23–47% at both 6 weeks and the end of the follow-up period. At the end of the follow-up period, 19 of the 55 women (34.5%) were cured (requiring no further treatment) and 12 (21.8%) were significantly improved (requiring only ongoing oral medication). Univariate and multivariate analyses showed that DMSO treatment failure was more likely in patients with pretreatment day-time urinary frequency more than 15 episodes per day (OR 1.41), nocturia more than two episodes per night (OR 2.47), maximum bladder diary voided volume <200 ml (OR 1.39) and bladder capacity under anaesthesia <500 ml (OR 1.6).

Conclusions

At a median follow-up of 60 months, intravesical DMSO cocktail therapy appeared moderately effective for the treatment of IC/BPS. Treatment failure was more frequent in patients with pretreatment symptoms of reduced bladder capacity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–1553.

    Article  PubMed  Google Scholar 

  2. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ. Epidemiology of interstitial cystitis: a population based study. J Urol. 1999;161:549–552.

    Article  CAS  PubMed  Google Scholar 

  3. Ibrahim IA, Diokno AC, Killinger KA, Carrico DJ, Peters KM. Prevalence of self-reported interstitial cystitis (IC) and interstitial-cystitis-like symptoms among adult women in the community. Int Urol Nephrol. 2007;39:489–495.

    Article  PubMed  Google Scholar 

  4. Berry SH, Stoto MA, Elliot M, Suttorp M, Bogart L, Eggers PW, et al. Prevalence of interstitial cystitis/painful bladder syndrome in the United States. J Urol. 2009;181(4 Suppl):20–21.

    Article  Google Scholar 

  5. Shirley SW, Stewart BH, Mirelman S. Dimethyl sulfoxide in treatment of inflammatory genitourinary disorders. Urology. 1978;11:215–220.

    Article  CAS  PubMed  Google Scholar 

  6. Ghoneim GM, McBride D, Sood OP, Lewis V. Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy. World J Urol. 1993;11:178–182.

    Google Scholar 

  7. Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide for interstitial cystitis – a practical approach. Urology. 1997;49(5A Suppl):105–107.

    Article  CAS  PubMed  Google Scholar 

  8. Rössberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand J Urol Nephrol. 2005;39(1):73–77.

    Article  PubMed  Google Scholar 

  9. Gafni-Kane A, Botros SM, Du H, Sand RI, Sand PK. Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2013;24:303–311.

    Article  PubMed  Google Scholar 

  10. Hung M, Chen Y, Shen P, Hsu S, Chen G, Ho E. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23:1533–1539.

    Article  PubMed  Google Scholar 

  11. Stav K, Beberashvili I, Lindner A, Leibovici D. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80(1):61–65.

    Article  PubMed  Google Scholar 

  12. van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol. 2005;174(5):1837–1840.

    Article  PubMed  Google Scholar 

  13. Al-Zahrani AA, Gajewski JB. Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome. Can Urol Assoc J. 2011;5(2):113–118.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004;171(6 Pt 1):2138–2141.

    Article  CAS  PubMed  Google Scholar 

  15. Hillelsohn JH, Rais-Bahrami S, Friedlander JI, Okhunov Z, Kashan M, Rosen L, Moldwin RM. Fulguration for Hunner ulcers: long-term clinical outcomes. J Urol. 2012;188(6):2238–2241.

    Article  PubMed  Google Scholar 

  16. Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2011;22(4):401–405.

    Article  PubMed  Google Scholar 

  17. Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol. 2005;39(2):143–147.

    Article  CAS  PubMed  Google Scholar 

  18. Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58:360–365.

    Article  CAS  PubMed  Google Scholar 

  19. Lee CL, Kuo HC. Long-term efficacy and safety of repeated intravesical onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/bladder pain syndrome. Toxins (Basel). 2015;7(10):4283–4293.

    Article  CAS  Google Scholar 

  20. Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up. Neurourol Urodyn. 2011;30(7):1271–1275.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urogynaecology, Mercy Hospital for Women, 163 Studley Road, Heidelberg, VIC, 3084, Australia

    Yik N. Lim, Peter Dwyer, Christine Murray, Debjyoti Karmakar & Elizabeth Thomas

  2. Monash Medical Centre, Melbourne, VIC, Australia

    Anna Rosamilia

Authors
  1. Yik N. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Dwyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Debjyoti Karmakar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Rosamilia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elizabeth Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yik N. Lim.

Ethics declarations

Funding

None.

Conflicts of interest

The authors have received research grants from AMS & Boston Scientific for other studies not related to this study.

Ethical approval

Approval for data collection was provided by Mercy Health Human Research & Ethics Committee (R15/02).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lim, Y.N., Dwyer, P., Murray, C. et al. Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome. Int Urogynecol J 28, 1085–1089 (2017). https://doi.org/10.1007/s00192-016-3232-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-016-3232-0

Keywords

Search

Navigation